<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7456638\results\search\testTrace\results.xml">
  <result pre="now, and most human influenza cases are due to the" exact="infection" post="of two IAV strains, H1N1 and H3N2. IAV have"/>
  <result pre="non-pulmonary cells, alveolar epithelial cells, and lung tissue after IAV" exact="infection" post="[10, 11], suggesting its potential as the target for"/>
  <result pre="[10, 11], suggesting its potential as the target for the" exact="treatment" post="of IAV infection. One of the PARP inhibitors, olaparib,"/>
  <result pre="The murine model of viral pneumonia was constructed by intranasal" exact="infection" post="with H1N1 according to previously described [13]. Briefly, ketamine"/>
  <result pre="blanket for 20Â min to recover. The day of virus" exact="infection" post="was defined as experimental day 1 and 0-days post-infection."/>
  <result pre="as experimental day 1 and 0-days post-infection. Grouping and drug" exact="treatment" post="Two grouping methods were applied in this study. For"/>
  <result pre="at âˆ’â€‰80Â Â°C for measurement of cytokine levels. MPO activity" exact="detection" post="MPO activity was assessed by 3,3â€²,5,5â€™-Tetramethylbenzidine (TMB, Sigma-Aldrich, St."/>
  <result pre="target factors was expressed as pg/mg protein for lung homogenate" exact="detection" post="and pg/ml for BALF detection. Real-time quantitative polymerase chain"/>
  <result pre="lung homogenate detection and pg/ml for BALF detection. Real-time quantitative" exact="polymerase chain reaction" post="(RT-qPCR) Viral load was determined by RT-qPCR according to"/>
  <result pre="PARylated protein content in the lung tissues was analyzed by" exact="western blot." post="Briefly, âˆ’â€‰80Â Â°C stored lung homogenate samples were thawed"/>
  <result pre="for 2Â days before viral challenge and 6Â days after" exact="infection" post="and survival for 15 consecutive days. Oseltamivir was used"/>
  <result pre="***pâ€‰ Olaparib relieved IAV-induced lung injury in mice As olaparib" exact="treatment" post="evidently reduced the virus-induced mortality, pathological changes were further"/>
  <result pre="significantly higher than that in the control group, and olaparib" exact="treatment" post="remarkably reduced the lung index, suggesting that olaparib could"/>
  <result pre="that olaparib could alleviate the pulmonary edema induced by IVA" exact="infection" post="(Fig.Â 2a). As shown in Fig. 2b, higher mRNA"/>
  <result pre="the control lung tissues, indicating the direct relationship between IAV" exact="infection" post="and pathological manifestations of mice model. Unsurprisingly, less IAV"/>
  <result pre="of this drug functions in the IAV model mice. Virus" exact="infection" post="always correlated with leukocyte filtration to the target organs."/>
  <result pre="of leucocytes, in lung tissues. Figure 2c showed that IAV" exact="infection" post="elevated the MPO levels compared with that in the"/>
  <result pre="lead to the breathing difficulty in infected mice. And olaparib" exact="treatment" post="attenuated the pathological abnormalities in IAV lungs. Lung histopathological"/>
  <result pre="pointed that olaparib rectified the lung injury caused by IAV" exact="infection" post="(Fig. 2e). Fig. 2 Effects of olaparib on influenza"/>
  <result pre="IL-10, was remarkably descended in the IAV group, while olaparib" exact="treatment" post="obviously rectified the abnormal release of the above inflammatory"/>
  <result pre="**pâ€‰ Olaparib reduced IAV-induced cytokine release in murine BALF The" exact="detection" post="of cytokine/chemokine in BALF samples at day 6 post-infection"/>
  <result pre="group compared with those in the control group, while olaparib" exact="treatment" post="significantly reduced the abnormal increased levels of the above"/>
  <result pre="protective effect of olaparib against IAV-induced injury to murine lungs," exact="western blot" post="was performed to detect the PARPs, the marker of"/>
  <result pre="performed to detect the PARPs, the marker of apoptosis. IAV" exact="infection" post="increased the PARylated protein content in lung homogenate samples"/>
  <result pre="sialic acid to initiate endocytosis [18]. Severe symptoms after IAV" exact="infection" post="are commonly found in the infant, elderly, pregnant, as"/>
  <result pre="the first time the possible role of olaparib on IAV" exact="infection" post="in a murine model and found that PARP-1 inhibitor"/>
  <result pre="phosphorylation. PARP has been indicated to be the target of" exact="treatment" post="strategy against cancers and inflammatory disorders [23, 24]. The"/>
  <result pre="PARP-1 might be a convincing target for the prevention and" exact="treatment" post="of lung inflammatory injury. Genetic as well as pharmacological"/>
  <result pre="exert non-specific anti-inflammatory roles. As the outbreak of severe coronavirus" exact="infection" post="since December 2019, it is urgent to explore the"/>
  <result pre="experimental virus-induced pneumonia, suggesting its possible application in viral pneumonia" exact="treatment" post="in the future. There are some shortcomings in our"/>
  <result pre="lung disorders and would shine light on the development for" exact="treatment" post="against pneumonia infected by viable IAV subtypes. Electronic supplementary"/>
  <result pre="alcohol isolated from Pogostemonis Herba augments protection against influenza viral" exact="infection" post="in miceInt Immunopharmacol201212129430110.1016/j.intimp.2011.12.00722193241 18.HutchinsonECInfluenza VirusTrends Microbiol201826980981010.1016/j.tim.2018.05.01329909041 19.Vazquez-PerezJADe La Rosa-ZamboniDVega-SanchezAEGutierrez-GonzalezLHTellez-NavarreteNACamposFGuadarrama-PerezCSandovalJLCastillejos-LopezMJimenez-JuarezRNSanchez-HuertaJLPerez-MendezBBPerez-PadillaRAmino"/>
  <result pre="OC43, HKU1, NL63, and 229E associated with severe acute respiratory" exact="infection" post="and fatality cases among healthy adults. J Med Virol."/>
 </snippets>
</snippetsTree>
